Novel RXFP1 modulators improve pharmacokinetics and physical properties to sustain pressure-lowering and cardiac benefits in resistant hypertension.
A fixed-dose ARB, diuretic, and calcium channel blocker improves blood pressure control while limiting side effects and simplifying treatment.